Langlois Sophia J. 4

What Happened

• Sophia J. Langlois, a director of Keenova Therapeutics plc, received a grant of 4,406 restricted stock units (RSUs) reported on Form 4. The RSUs were granted on July 15, 2026, recorded at $0.00 per share (an award/derivative grant rather than a purchase or sale). The filing was made July 17, 2026.

Key Details

• Transaction date: 2026-07-15; filing date: 2026-07-17.
• Transaction type/code: A (award/grant of derivative securities — RSUs).
• Number granted: 4,406 RSUs; grant price shown as $0.00 (no cash paid).
• Settlement: Each RSU will be settled in one ordinary share upon vesting (1 RSU = 1 share).
• Vesting: RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the issuer’s next annual general meeting of shareholders.
• Shares owned after transaction: not disclosed in the provided excerpt.
• Remarks: The Form 4 also serves as a notice to the issuer under Part V of the Companies Act 2014.

Context

• This is a compensation award (RSUs) rather than an open-market purchase or sale; such grants are commonly used for director compensation and do not by themselves indicate buying or selling sentiment. The RSUs are derivative awards that will convert to ordinary shares when they vest per the stated schedule.